Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 16, Issue Suppl 3
0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
ABSTRACT: Poster Session 1: Ovarian – Sunday, October 15, 2006
0218: Phase II Study of Pegylated Liposomal Doxorubi-Cin (Pld) Plus Oxaliplatin (Oxa) for Resistant or Refractory Ovarian Cancer Patients
Online download statistics by month:
Online download statistics by month:
No statistics are available.
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
